HRH3 and schizophrenia: Even though the preclinical studies in pharmacological models of schizophrenia have shown the protective effects of H3R inverse agonists, such as ABT-239, pitolisant, GSK207040, on the locomotor hyperactivity, the cognitive and sensory gating deficits, the clinical results of H3R inverse agonists in schizophrenia were disappointing unfortunately [80,81,82].